Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device (VOYAGER)

An Early Feasibility Study to Evaluate the Safety of the TheraSphere Prostate Cancer (PCa) Device in Patients With Clinically Localized Prostate Cancer

The VOYAGER Study is an interventional, non-randomized, single-arm, dose escalation trial with the goal of determining the safety of TheraSphere PCa device in patients with clinically localized prostate cancer across US-based centers.

Study Overview

• Status: Active, not recruiting
• Conditions: Cancer; Prostate
• Intervention / Treatment: Device: TheraSphere PCa

Detailed Description

TheraSphere™ Y-90 Glass Microspheres are a targeted cancer therapy consisting of tiny glass beads containing radioactive Yttrium-90 (Y-90), which are injected directly into the blood vessel feeding the tumor through a microcatheter using advanced imaging guidance. The glass microspheres enter the tumor's blood supply, lodge within the blood vessels feeding the tumor, and release radiation to the tumor. The radiation works to destroy the tumor cells from within, thus limiting radiation exposure to surrounding normal tissues, a process referred to as selective internal radiation therapy (SIRT).

This study aims to investigate the maximum safe radiation dose of TheraSphere Prostate Cancer (PCa) device that can be delivered in patients with clinically localized prostate cancer. The study will also evaluate the full safety profile, technical feasibility, efficacy, and quality of life metrics of the TheraSphere PCa device.

Participants will be asked to complete the following:

• At least two image-guided visits, including a mapping assessment (without Technetium Tc albumin aggregated [Tc-MAA]) prior to treatment
• One treatment visit, including image-guided assessments
• Fifteen post-treatment follow-up visits for a total of approximately 20 visits over the 5-year study period

Note: the VOYAGER Study is a staged investigational device exemption (IDE) study; therefore, the full enrollment of 21 to 36 subjects is subject to FDA approval following safety review of the first 10 subjects enrolled.

• Study Type: Interventional
• Enrollment (Estimated): 36
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Illinois
    • Chicago, Illinois, United States, 60611
      • Northwestern Memorial Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Subject has ability to comprehend and willingness to sign and date the IRB-approved study informed consent form (ICF), and to comply with the study testing, procedures, and follow-up schedule.
2. Histologic confirmation of adenocarcinoma of the prostate by MR-fusion biopsy. Referral biopsy for eligibility must be completed between 180 days and 6 weeks prior to mapping procedure.

3. Subject with favorable intermediate risk clinically localized prostate cancer defined per NCCN Guidelines version 3.2022 as follows:

   • Favorable intermediate-risk has all the following:

   • i. One Intermediate Risk Factor (IRF):

     1. cT2b-cT2c
     2. Grade Group 2 or 3
     3. PSA 10-20 ng/mL
   • ii. Grade Group 1 or 2
   • iii. <50% biopsy cores positive (e.g., <6 of 12 cores)
4. Staging MRI must confirm American Joint Committee on Cancer (AJCC, 8th edition) stage T1, T2a, T2b or T2c.
5. Whole prostate gland volume ≥ 60 cc (measured on MRI)
6. International Prostate Score Symptom (I-PSS) ≤ 18
7. Estimated life expectancy of >5 years according to NCCN guideline's tools (NCCN v03.2022) who has declined or is ineligible for Standard of Care treatments (observation, active surveillance, surgery, and radiation therapies [brachytherapy/external beam radiation therapy])
8. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

9. Angiographic inclusion criteria:

   • a. Type I to IV prostate artery origins on both hemiglands.1
   • b. No evidence of procedure limiting vascular abnormalities (aneurysms, stenosis, shunt, fistula, occlusion) or morphologic asymmetric single prostate artery on either side (hemigland)
   • c. Bilaterally accessible solitary prostatic arteries.
   • d. Complete perfusion of the prostate gland via a single dominant vessel for each hemigland

10. Have adequate organ and bone marrow function within 30 days prior to index procedure, as defined below:

    • a. International Normalized Ratio (INR) ≤ 1.2 (in absence of anticoagulation)
    • b. Platelets ≥ 75,000/L
    • c. GFR ≥ 40 mL/min/1.73m2
    • d. Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L
    • e. Hemoglobin (Hgb) ≥ 9.0 g/dL (Note: the use of transfusion or other intervention to achieve adequate bone marrow function is acceptable
    • f. ALT/AST ≤ 5 x upper limit of normal (ULN)
    • g. Bilirubin ≤ 2 mg/dL
11. Patients with known Human Immunodeficiency Virus (HIV) infection are eligible with well controlled HIV infection, no current or previous AIDS-related complications and CD4+ T-cell (CD4+) counts ≥ 350 cells/uL

Exclusion Criteria:

1. Direct evidence of regional or distant metastases after appropriate staging studies per NCCN guidelines (v03.2022)
2. Histological evidence of intraductal features
3. Previous treatments (pelvic radiotherapy, surgery, prostate artery embolization [PAE], transurethral resection of the prostate [TURP] or previous/ planned hormonal therapy
4. History of Crohn's Disease, ulcerative colitis, or ataxia telangiectasia, current gross haematuria, or current urinary catheter
5. Subjects with ongoing urinary tract infection, prostate abscess, prostatitis, or neurogenic bladder
6. Prior significant rectal surgery (haemorrhoidectomy is acceptable)
7. Prior invasive malignancy unless disease free for a minimum of 3 years. Exceptions to this requirement include adequately treated non-melanoma skin cancer or lentigo maligna or carcinoma in situ without evidence of disease
8. Hip prosthesis
9. Medical contraindication to undergo contrast-enhanced angiography, CT scan and magnetic resonance imaging (MRI), or arterial catheterization, or known history of hypersensitivity reactions to iodinated and gadolinium-based contrast product

10. Angiographic exclusion criteria:

    • a. Perfusion to tissues outside the Planning Target Volume (PTV) that cannot be corrected by placement of the catheter distal to collateral vessels or the application of standard angiographic techniques, such as coil embolization
    • b. Type V prostatic artery origin on either side

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: TheraSphere PCa Dose Escalation; Participants will be treated in cohorts of three across three sequential dose levels: Dose Level 1 (or starting dose) = 175 Gy; however, a provisional lower dose level, Dose Level -1 = 150 Gy, may be utilized in case de-escalation is warranted at Dose Level 1.; Dose Level 2 = 200 Gy; Dose Level 3 = 225 Gy	Device: TheraSphere PCa; Single session treatment of TheraSphere PCa - Yttrium-90 Glass Microspheres for the treatment of prostate cancer. Dose vials will be available in activity ranging from 0.1 GBq (2.7 mCi) to 3 GBq (81 mCi).; Other Names: TheraSphere PCa - Yttrium-90 Glass Microspheres

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum tolerated radiation dose of TheraSphere PCa	• The Maximum Tolerated Dose (MTD) of Yttrium-90 Glass Microspheres (TheraSphere™ PCa) is based on rate of dose limiting toxicity (DLT) through 90 days, defined as any ≥ grade 3 adverse event (AE) according to CTCAE v.5	Through 90 days post-treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of adverse events (AEs)	The following AEs/SAEs will be assessed in accordance with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0: Rate of any ≥ grade 3 AEs; Rate of AEs of interest, i.e., any ≥ Grade 2 GI/GU and erectile dysfunction toxicities; Rate of any treatment-emergent AEs and treatment-emergent SAEs; Rate of any treatment-related AEs and treatment-related SAEs; AEs related to non-target TheraSphere PCa distribution	Through 5 years post-treatment (acute ≤ 90 days and late > 90 days)
Rate of success of delivering intended dose	• The ability to deliver the intended TheraSphere PCa absorbed dose (+/- 20%) to the treatment volume based on post-treatment PET derived absorbed dose.	Immediately post-treatment
Recurrence Free Survival	• Biochemical Recurrence Free Survival (bRFS) based on PSA according to the Phoenix criteria (RTOG-ASTRO definition). Biochemical recurrence of prostate cancer after curative treatment is defined as a PSA rise of ≥ 2 ng/mL above the post-treatment nadir.	Through 5 years post-treatment
Progression free survival (PFS)	• Progression free survival (PFS) and local progression free survival (LPFS), defined as time from inclusion until one of the following events, whichever comes first: biochemical progression (Phoenix criteria) or clinical progression.	Through 5 years post-treatment
Prostate cancer specific survival	• Prostate cancer specific survival will be measured as the number of days between treatment with TheraSphere PCa and death by prostate cancer.	Through 5 years post-treatment
Overall survival (OS)	• OS will be measured as the number of days between treatment with TheraSphere PCa and death by any cause.	Through 5 years post-treatment
Rate of subsequent prostate anticancer treatment	• A summary table with number of subjects (%) who received subsequent definitive or systematic therapy and type of therapies received will be presented.	Through 5 years post-treatment
Rate of histopathological recurrence	• Rate of recurrence based on histopathological assessment of prostate MR/US-fusion biopsy in patients with evidence of progression.	Through 5 years post-treatment
Quality of Life (QoL) measured by EPIC-26	• Change from baseline measured through Expanded Prostate Cancer Index Composite (EPIC-26).	Through 5 years post-treatment
Quality of Life (QoL) measured by MSHQ	• Change from baseline measured through Male Sexual Health Questionnaire (MSHQ).	Through 5 years post-treatment
Quality of Life (QoL) measured by I-PSS	• Change from baseline measured through International Prostate Symptom Score (I-PSS).	Through 5 years post-treatment
Maximum urinary flow (Qmax)	• Change from baseline	Through 5 years post-treatment
Post-void residual (PVR) urine test	• Change from baseline	Through 5 years post-treatment
Dose Distribution	• Dose Volume Histogram (DVH) and evaluation of D90 from post-treatment Y90 PET-MRI/CT.	Through one-week post-treatment

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prostatic imaging assessment	• Qualitative analysis of multi-parametric MRI (mp-MRI) and PI-RADS score	Through 5 years post-treatment

Collaborators and Investigators

• Sponsor: Boston Scientific Corporation
• Investigators: Principal Investigator: Samdeep Mouli, M.D., M.S., Northwestern Medical Hospital; Principal Investigator: Mark Hurwitz, MD, Westchester Medical Center

Publications and helpful links

General Publications

• Mouli SK, Raiter S, Harris K, Mylarapu A, Burks M, Li W, Gordon AC, Khan A, Matsumoto M, Bailey KL, Pasciak AS, Manupipatpong S, Weiss CR, Casalino D, Miller FH, Gates VL, Hohlastos E, Lewandowski RJ, Kim DH, Dreher MR, Salem R. Yttrium-90 Radioembolization to the Prostate Gland: Proof of Concept in a Canine Model and Clinical Translation. J Vasc Interv Radiol. 2021 Aug;32(8):1103-1112.e12. doi: 10.1016/j.jvir.2021.01.282. Epub 2021 Apr 9.
• Yuan Y, Lin R, Li D, Nie L, Warren KE. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials. Clin Cancer Res. 2018 Oct 15;24(20):4921-4930. doi: 10.1158/1078-0432.CCR-18-0246. Epub 2018 May 16.
• Meiselman S, Thomas MA, Giardina JD, Zheleznyak A, Thorek DLJ, Malone CD. Advances in Radioembolization for Liver Cancer. J Vasc Interv Radiol. 2025 Dec;36(12):1876-1881. doi: 10.1016/j.jvir.2025.07.018.

Study record dates

Study Major Dates

• Study Start (Actual): April 15, 2024
• Primary Completion (Estimated): January 1, 2028
• Study Completion (Estimated): October 1, 2032

Study Registration Dates

• First Submitted: November 28, 2023
• First Submitted That Met QC Criteria: December 21, 2023
• First Posted (Actual): January 5, 2024

Study Record Updates

• Last Update Posted (Actual): June 2, 2026
• Last Update Submitted That Met QC Criteria: May 29, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: Microspheres; Radiation; TheraSphere; Yttrium-90; Y90; Glass
• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Prostatic Diseases; Male Urogenital Diseases; Neoplasms; Chromosome 2q32-Q33 Deletion Syndrome
• Other Study ID Numbers: S2493

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No